FDA Acceptance of Supplemental NDA for RIMACTANE by Oxford Pharms
The FDA has accepted the supplemental NDA for RIMACTANE (Rifampin) submitted by Oxford Pharms, with a standard review priority.
Asset / Drug
Drug and asset intelligence for RIMACTANE with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.